Ginkgo Bioworks (NYSE:DNA - Get Free Report) will announce its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($2.40) per share for the quarter. Ginkgo Bioworks has set its FY 2024 guidance at EPS.Investors that are interested in registering for the company's conference call can do so using this link.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($3.20) earnings per share for the quarter, hitting analysts' consensus estimates of ($3.20). Ginkgo Bioworks had a negative net margin of 486.98% and a negative return on equity of 63.09%. The business had revenue of $56.21 million during the quarter, compared to analyst estimates of $41.46 million. On average, analysts expect Ginkgo Bioworks to post $-6 EPS for the current fiscal year and $-8 EPS for the next fiscal year.
Ginkgo Bioworks Trading Up 4.0 %
Shares of NYSE:DNA traded up $0.32 during midday trading on Wednesday, reaching $8.31. 841,266 shares of the company were exchanged, compared to its average volume of 1,127,491. The company's fifty day moving average is $7.53. Ginkgo Bioworks has a one year low of $5.26 and a one year high of $75.20. The firm has a market capitalization of $461.87 million, a PE ratio of -0.44 and a beta of 1.09.
Analysts Set New Price Targets
A number of brokerages recently weighed in on DNA. The Goldman Sachs Group dropped their target price on shares of Ginkgo Bioworks from $0.80 to $0.30 and set a "sell" rating for the company in a research report on Tuesday, July 9th. TD Cowen upped their target price on shares of Ginkgo Bioworks from $3.00 to $10.00 and gave the stock a "buy" rating in a research report on Friday, September 20th. Finally, BTIG Research upped their target price on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the stock a "sell" rating in a research report on Friday, August 23rd. Three analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, Ginkgo Bioworks presently has a consensus rating of "Hold" and an average price target of $4.16.
Check Out Our Latest Stock Report on Ginkgo Bioworks
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Read More
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
